Beijing Hotgen Biotech Co Ltd

688068 · SHG · Healthcare / Biotechnology

68.13CNY-2.76 (-3.89%)

Price History

Full chart

Market Stats

Previous Close70.89

Open70.53

Day Range67.68 – 71.00

52-Week Range73.44 – 214.78

Volume1.80M

Market Cap8.76B

P/E (TTM)0.00

Forward P/E0.00

EPS-2.94

Dividend Yield0.00%

Beta0.37

50-Day Avg101.06

200-Day Avg118.36

About

Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers nucleic acid drugs, antibody drugs, and biotechnology health and beauty consumer products. The company also provides clinical diagnostics and product solutions, including Upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is based in Beijing, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Changqing Lin
Employees1.04K
HeadquartersNo. 55, Qingfeng West Road, Beijing, China, 102629, China
Websitehttps://www.hotgen.com.cn

Leadership

Mr. Changqing LinChairman & GM · b. 1976
Mr. Zhongchao JieFinancial Director & Accounting Supervisor · b. 1980
Mr. Yongzhan ShiDeputy GM, Secretary & Director · b. 1982
Ms. Jia LiuDeputy General Manager · b. 1987
Ms. Hongrui ZhangCore Technical Personnel · b. 1986
Ms. Suhong ChenCore Technical Personnel · b. 1986
Ms. Yong QiaoCore Technical Personnel · b. 1983
Mr. Kun HaoCore Technical Personnel · b. 1986
Mr. Zhihui XuCore Technical Personnel · b. 1982

Financials

Income Statement

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	122.20M	142.09M	187.12M	210.41M	513.53M	5.37B	3.56B	547.84M	510.90M	407.69M
Growth (%)	-	+16.28%	+31.69%	+12.45%	+144.06%	+945.54%	-33.76%	-84.60%	-6.74%	-20.20%
Cost of Revenue	29.53M	36.83M	49.13M	56.55M	189.95M	2.25B	1.77B	211.72M	257.18M	171.78M
Gross Profit	92.67M	105.25M	137.99M	153.86M	323.59M	3.12B	1.79B	336.11M	253.72M	407.69M
Gross Margin	75.84%	74.08%	73.74%	73.12%	63.01%	58.03%	50.34%	61.35%	49.66%	100.00%
Operating Expense	62.59M	70.66M	82.18M	116.49M	195.64M	531.17M	699.43M	317.42M	439.31M	670.27M
Operating Income	30.08M	34.60M	55.81M	37.37M	127.95M	2.58B	1.09B	18.69M	-185.59M	-262.58M
Operating Margin	24.62%	24.35%	29.82%	17.76%	24.92%	48.13%	30.67%	3.41%	-36.33%	-64.41%
EBITDA	41.40M	44.97M	72.16M	61.19M	157.02M	2.64B	1.17B	77.31M	-102.98M	-180.44M
EBITDA Margin	33.88%	31.65%	38.56%	29.08%	30.58%	49.18%	32.82%	14.11%	-20.16%	-44.26%
Net Income	28.80M	30.07M	48.14M	33.88M	112.07M	2.19B	944.74M	28.92M	-191.00M	-210.52M
Net Income Margin	23.57%	21.16%	25.73%	16.10%	21.82%	40.71%	26.56%	5.28%	-37.39%	-51.64%
R&D	13.29M	15.63M	18.38M	28.99M	47.61M	131.92M	191.14M	132.88M	113.31M	162.28M
R&D as % of Total Revenue	10.88%	11.00%	9.82%	13.78%	9.27%	2.46%	5.37%	24.26%	22.18%	39.81%
Interest Expense	0	0	46.14K	1.36M	449.83K	1.35M	2.58M	1.12M	556.71K	8.80M
Interest Expense % of Total Revenue	0.00%	0.00%	0.02%	0.65%	0.09%	0.03%	0.07%	0.20%	0.11%	2.16%

Balance Sheet

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	160.12M	189.65M	267.12M	725.67M	902.52M	3.64B	3.90B	3.56B	3.33B	3.18B
Total Liabilities	29.14M	28.00M	56.68M	76.37M	155.72M	771.01M	545.59M	202.56M	251.77M	-2.93B
Total Equity	130.98M	161.65M	209.79M	645.16M	742.73M	2.84B	3.34B	3.37B	3.08B	2.93B
Cash	96.49M	48.60M	63.77M	422.85M	382.62M	1.16B	523.49M	272.39M	270.15M	536.84M
Total Debt	3.18M	155.58K	-	23.75M	26.50M	35.98M	42.13M	15.26M	121.00K	-
Net Debt	-93.31M	-48.44M	-63.77M	-399.10M	-356.12M	-1.13B	-481.36M	-257.14M	-270.03M	-

Cash Flow

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	45.54M	22.95M	55.04M	19.37M	164.62M	2.64B	978.75M	-25.39M	-37.16M	-83.36M
Investing Cash Flow	-20.77M	-67.56M	-40.58M	-85.86M	-164.10M	-1.76B	-1.13B	-161.87M	110.83M	-
Financing Cash Flow	51.41M	-3.23M	437.87K	425.44M	-42.16M	-95.07M	-484.99M	-36.55M	-79.48M	-
Capital Expenditure	21.18M	69.05M	42.00M	88.48M	172.27M	398.86M	565.21M	413.37M	51.41M	43.57M
Free Cash Flow	24.36M	-46.10M	13.03M	-69.11M	-7.65M	2.25B	413.54M	-465.31M	-88.57M	-126.93M
Dividends Paid	2.30M	26.63K	3.28K	1.03M	18.66M	93.29M	310.98M	-	17.34M	1.74M
FCF to OCF	53.49%	-200.86%	23.68%	-356.76%	-4.64%	84.92%	42.25%	1832.91%	238.33%	152.27%
Dividend Paid to FCF	9.45%	-0.06%	0.03%	-1.50%	-244.04%	4.15%	75.20%	-	-19.58%	-1.37%

Earnings

Report Date	Aug 25, 2019	Oct 29, 2019	Feb 27, 2020	Apr 22, 2020	Aug 25, 2020	Oct 29, 2020	Dec 31, 2020	Apr 23, 2021	Aug 26, 2021	Oct 29, 2021	Dec 31, 2021	Apr 22, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023
EPS Estimate	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	0.25	0.03	0.22	0.01	0.01	0.03	1.16	9.67	13.69	0.38	7.71	6.58	2.27	3.11	-1.75	0.66
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	-	Pre-market	-	-	-	Pre-market	-	-	-	-

Key Statistics & Ratios

Market Cap8.76B

Enterprise Value7.65B

Trailing P/E0.00

Forward P/E0.00

Price / Sales18.68

Price / Book3.63

EPS-2.94

Book Value27.69

Revenue (TTM)469.17M

Gross Profit (TTM)287.12M

EBITDA-249.26M

Profit Margin-55.30%

Operating Margin-47.10%

Return on Equity-11.65%

Return on Assets-6.45%

Shares Outstanding92.75M

Shares Float60.02M

Beta0.37

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20241×

0.20Jul 3, 2024

20221×

5.00Jun 16, 2022

20211×

1.01Jun 25, 2021

20201×

0.20Jun 24, 2020

Stock Splits

Jun 16, 20221.48:1